Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC

October 3rd 2023

The FDA has granted a fast track designation to BI 764532 for the treatment of patients with extensive-stage small cell lung cancer that has progressed following at least 2 prior lines of treatment, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma that has progressed following at least 1 prior line of treatment.

Treating MET Exon 14 NSCLC

October 3rd 2023

The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.

Approach to Treating Patients with NSCLC and RET Fusions

October 3rd 2023

Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.

Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

October 2nd 2023

Takeda has announced plans to voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell lung cancer whose disease has progressed on or following platinum-based chemotherapy.

FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC

October 1st 2023

The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.

Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC

September 29th 2023

Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.

Dr Ricciuti on PD-L1 Expression and Long-Term Survival Outcomes With PD-L1 Inhibitors in Advanced NSCLC

September 29th 2023

Biagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.

Mechanisms of Action of Antibody-Drug Conjugates

September 29th 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

Overview of Antibody-Drug Conjugates (ADCs)

September 29th 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

Dr Bodor on a Study Profiling Estrogen Species in Women With EGFR-Mutated NSCLC

September 28th 2023

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Dr Aredo on the Molecular Distribution of Screening-Eligible Patients With NSCLC

September 28th 2023

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

First-Line Amivantamab Plus Lazertinib Meets PFS End Point in EGFR+ NSCLC

September 28th 2023

First-line treatment with the combination of amivantamab and lazertinib resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

September 28th 2023

Treatment with the combination of sotorasib carboplatin, and pemetrexed produced responses and demonstrated safety in patients with KRAS G12C–mutated, advanced non–small cell lung cancer, according to data from the phase 1/2 CodeBreaK 101 trial.

Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment

September 27th 2023

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.

Dr Billè on the Use of Minimally Invasive Surgery vs Stereotactic Radiotherapy in NSCLC

September 27th 2023

Andrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.

FDA Grants Fast Track Status to MYTX-011 for NSCLC With cMET Overexpression

September 26th 2023

The FDA has granted fast track designation to MYTX-011 for use as a potential therapeutic option in patients with non–small cell lung cancer and cMET overexpression.

Multidisciplinary Approaches Shape Treatment Pathways in EGFR-Mutated NSCLC

September 26th 2023

Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.

Treatment of NTRK Fusions in NSCLC

September 26th 2023

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.

Choosing Between ALK Inhibitors in the Treatment of NSCLC

September 26th 2023

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

Dr Riess on the Initial Efficacy of the IO102-IO103 Vaccine Plus Pembrolizumab in Lung Adenocarcinoma

September 25th 2023

Jonathan W. Riess, MD, MS, discusses preliminary results from a phase 2 trial of the IO102-IO103 immuno-modulating cancer vaccine plus pembrolizumab in patients with metastatic non–small cell lung cancer adenocarcinoma.